Global Liver Cirrhosis Therapeutics Market 2024-2028
The liver cirrhosis therapeutics market is forecasted to grow by USD 1.94 bn during 2023-2028, accelerating at a CAGR of 5.58% during the forecast period. The report on the liver cirrhosis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of liver cancer, advancements in medical research, and increasing collaborations between pharmaceutical companies and healthcare providers.
Technavio's liver cirrhosis therapeutics market is segmented as below:
By Type
By End-user
- Hospitals
- Clinics
- Research and academic institutes
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the trend towards personalized medicine as one of the prime reasons driving the liver cirrhosis therapeutics market growth during the next few years. Also, increasing emphasis on non-invasive treatment options and integration of digital health technologies will lead to sizable demand in the market.
The report on the liver cirrhosis therapeutics market covers the following areas:
- Liver cirrhosis therapeutics market sizing
- Liver cirrhosis therapeutics market forecast
- Liver cirrhosis therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading liver cirrhosis therapeutics market vendors that include AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, CSL Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Gwo Xi Stem Cell Applied Technology, Johnson and Johnson, Kezar Life Sciences Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Protagonist Therapeutics Inc., and Tessera Therapeutics. Also, the liver cirrhosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.